【摘要】 目的:评价卡马西平治疗糖尿病痛性神经病变的临床疗效及安全性。方法:将53例糖尿病痛性神经病变患者随机分为两组,对照组27例,在胰岛素强化控制血糖及良好控制血压、血脂的基础上,应用生理盐水250 ml+盐酸丁咯地尔注射液0.1 g,静脉滴注/天;治疗组26例,在对照组治疗基础上加用卡马西平0.1 g,每日3次。进行随机双盲对照研究,疗程14～21天。采用VRS5疼痛缓解标准评价卡马西平的疗效及安全性。结果:治疗组加用卡马西平后疗效优于对照组(P<0.01),疼痛缓解率达84.6%,治疗期间及治疗后无明显不良反应发生。结论:卡马西平治疗糖尿病痛性神经病变的临床疗效明显,与对照组比较有显著性差异(P<0.01),疼痛缓解时间也较对照组明显为早(P<0.05),而且安全,无严重不良反应。更多还原

【Abstract】 Objective:To evaluate the clinical efficacy and safety of carbamazepine in the treatment of painful diabetic neuropathy.Methods:53 painful diabetic neuropathy patients were randomly divided into two groups;their blood pressure,blood lipids and blood glucose were all in the good control.The first group was the control group of 27 cases,they were treated with saline buflomedil injection(0.1g intravenous drip/day);the second group was therapy group of 26 cases,they were treated with saline buflomedil injection(0.1g intravenous drip/day) and carbamazepine(0.1g tid).The treatment lasted for 14~21 days.A randomized double-blind study was applied in our study.Results:The efficacy of the therapy group was better than that of the control group(P<0.01),the pain remission rate was 84.6%.There was no adverse reaction during and after treatment.Conclusion:It was very useful and safe to treated painful diabetic neuropathy with carbamazepine.更多还原